The historical rank and industry rank for ArcticZymes Technologies ASA's Net Margin % or its related term are showing as below:
FRA:B4V'
s Net Margin % Range Over the Past 10 Years
Min: -37.4 Med: 8.39 Max: 88.95
Current: 11.59
FRA:B4V's Net Margin % is ranked better than 81.66% of 938
companies
in the Biotechnology industry
Industry Median: -88.09
vs FRA:B4V: 11.59
ArcticZymes Technologies ASA (FRA:B4V) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ArcticZymes Technologies ASA Net Margin % Related Terms
ArcticZymes Technologies ASA Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:B4V vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Net Margin % distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA (FRA:B4V) has a Net Margin % of 1.83% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ArcticZymes Technologies ASA and its competitors. This is 78% below median its historical median of 8.39. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #172 out of 938 companies in the Biotechnology industry, placing it in the top 18.3%.
Is ArcticZymes Technologies ASA's Net Margin % too high?
ArcticZymes Technologies ASA's current Net Margin % of 1.83% is 78% below median its 10-year median of 8.39. Based on the distribution chart, ArcticZymes Technologies ASA ranks #172 out of 938 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #172 out of 938 companies for Net Margin %. This places ArcticZymes Technologies ASA in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ArcticZymes Technologies ASA and its competitors. ArcticZymes Technologies ASA's current Net Margin % is 1.83%, which is 78% below median its own 10-year median of 8.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
ArcticZymes Technologies ASA (FRA:B4V) has a current Net Margin % of 1.83%. The stock's GF Value™ is €2.14, compared to a current price of €1.66 — trading 22.4% below its estimated fair value. The current Net Margin % is 1.83%, which is 78% below median its 10-year median of 8.39. ArcticZymes Technologies ASA's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ArcticZymes Technologies ASA (FRA:B4V), the current Net Margin % is 1.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (FRA:B4V) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of €1.66 is trading 22.4% below its estimated GF Value™ of €2.14.
Key valuation signals for FRA:B4V:
Net Margin %: 1.83% (78% below median its 10-year median of 8.39)
GF Value™: €2.14 vs. price of €1.66 (22.4% below fair value)
No single metric tells the full story. See the FRA:B4V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
79GF Score
Get the complete analysis for FRA:B4V
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B4V has been successfully added to your 
